JP2023550652A - 移植片対宿主病を処置するための設計された細菌組成物 - Google Patents

移植片対宿主病を処置するための設計された細菌組成物 Download PDF

Info

Publication number
JP2023550652A
JP2023550652A JP2023531555A JP2023531555A JP2023550652A JP 2023550652 A JP2023550652 A JP 2023550652A JP 2023531555 A JP2023531555 A JP 2023531555A JP 2023531555 A JP2023531555 A JP 2023531555A JP 2023550652 A JP2023550652 A JP 2023550652A
Authority
JP
Japan
Prior art keywords
composition
subject
species
bacteria
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023531555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550652A5 (cg-RX-API-DMAC7.html
Inventor
マシュー アール. ヘン,
エドワード ジェイ. オブライエン,
アンバー ピニャ,
マリン ヴリック,
クリストファー ビー. フォード,
アスンシオン マルティネス,
ディヴィヤ バラスブラマニアン,
エリザベス ハルヴォルセン,
カレン キーザー,
マフムード サレハ,
メアリー‐ジェーン ロンバード,
スモン ダッタ,
マドゥミタ ナンダクマール,
プリヤンカ ナレンダー,
カンカナ バーダン,
Original Assignee
セレス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレス セラピューティクス インコーポレイテッド filed Critical セレス セラピューティクス インコーポレイテッド
Publication of JP2023550652A publication Critical patent/JP2023550652A/ja
Publication of JP2023550652A5 publication Critical patent/JP2023550652A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Agronomy & Crop Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
JP2023531555A 2020-11-25 2021-11-24 移植片対宿主病を処置するための設計された細菌組成物 Pending JP2023550652A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063118639P 2020-11-25 2020-11-25
US63/118,639 2020-11-25
PCT/US2021/060878 WO2022115646A1 (en) 2020-11-25 2021-11-24 Designed bacterial compositions for treating graft-versus-host-disease

Publications (2)

Publication Number Publication Date
JP2023550652A true JP2023550652A (ja) 2023-12-04
JP2023550652A5 JP2023550652A5 (cg-RX-API-DMAC7.html) 2024-12-03

Family

ID=81756137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023531555A Pending JP2023550652A (ja) 2020-11-25 2021-11-24 移植片対宿主病を処置するための設計された細菌組成物

Country Status (9)

Country Link
US (1) US20240000859A1 (cg-RX-API-DMAC7.html)
EP (1) EP4250932A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023550652A (cg-RX-API-DMAC7.html)
KR (1) KR20230124601A (cg-RX-API-DMAC7.html)
CN (1) CN116709924A (cg-RX-API-DMAC7.html)
AU (1) AU2021388169A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199153A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006146A (cg-RX-API-DMAC7.html)
WO (1) WO2022115646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4341382A4 (en) * 2021-05-10 2025-04-30 Microba Ip Pty Ltd COMPOSITIONS AND METHODS FOR TREATING DISEASES
CN114788837B (zh) * 2022-06-07 2023-09-05 青岛东海药业有限公司 一种组合物及其在制备治疗和/或预防化疗引起的恶心呕吐的药物中的应用
EP4687930A2 (en) * 2023-01-30 2026-02-11 Seres Therapeutics, Inc. Use of designed bacterial compositions for infection treatment
GB2627012A (en) * 2023-02-13 2024-08-14 Acad Medisch Ct Predictive biomarker of neonatal E.coli mediated sepsis
AU2024327567A1 (en) * 2023-08-22 2026-01-08 Danisco Usa Inc. Methods and compositions for immune system regulation
CN117907608B (zh) * 2024-03-19 2024-05-24 苏州和锐生物科技有限公司 一种Claudin2蛋白的检测方法及其相关产品和应用
CN119055685A (zh) * 2024-09-13 2024-12-03 南方医科大学南方医院 粪副拟杆菌在制备分离移植物抗白血病效应与移植物抗宿主病药物中的应用
CN118987051A (zh) * 2024-09-13 2024-11-22 南方医科大学南方医院 粪副拟杆菌在制备治疗移植物抗宿主病药物中的应用
CN120700173B (zh) * 2025-09-01 2026-01-02 华中科技大学同济医学院附属协和医院 甲状腺相关眼病的微生物标志物、产品及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015537042A (ja) * 2012-11-23 2015-12-24 セレス セラピューティクス インコーポレイテッド 相乗的細菌組成物並びにその生成及び使用の方法
US20160235792A1 (en) * 2014-11-25 2016-08-18 Epiva Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
JP2016537434A (ja) * 2013-11-25 2016-12-01 セレス セラピューティクス インコーポレイテッド 相乗作用のある細菌組成物ならびにその製造及び使用方法
JP2019501136A (ja) * 2015-11-24 2019-01-17 セレス セラピューティクス インコーポレイテッド 設計された細菌組成物
JP2019508479A (ja) * 2016-03-14 2019-03-28 ホロバイオーム, インコーポレイテッド 中枢神経系の精神障害または疾患を処置するための腸ミクロビオームの改変

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2951283A4 (en) * 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
MX369877B (es) * 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
JP2016519664A (ja) * 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
EP3379935A4 (en) * 2015-11-25 2019-08-28 Memorial Sloan-Kettering Cancer Center METHOD AND COMPOSITIONS FOR REDUCING VANCOMYCIN RESISTANT ENTEROKOKKEN
KR102658297B1 (ko) * 2016-06-14 2024-04-18 베단타 바이오사이언시즈, 인크. 클로스트리디움 디피실레 감염의 치료
KR20200038506A (ko) * 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
JP2020530493A (ja) * 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド. 腸内の抗生物質耐性菌を除菌するための組成物及び方法
BR112020002992A2 (pt) * 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
JP2021512638A (ja) * 2018-02-09 2021-05-20 学校法人慶應義塾 Cd8+t細胞の誘導のための組成物および方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015537042A (ja) * 2012-11-23 2015-12-24 セレス セラピューティクス インコーポレイテッド 相乗的細菌組成物並びにその生成及び使用の方法
JP2016537434A (ja) * 2013-11-25 2016-12-01 セレス セラピューティクス インコーポレイテッド 相乗作用のある細菌組成物ならびにその製造及び使用方法
US20160235792A1 (en) * 2014-11-25 2016-08-18 Epiva Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
JP2019501136A (ja) * 2015-11-24 2019-01-17 セレス セラピューティクス インコーポレイテッド 設計された細菌組成物
JP2019508479A (ja) * 2016-03-14 2019-03-28 ホロバイオーム, インコーポレイテッド 中枢神経系の精神障害または疾患を処置するための腸ミクロビオームの改変

Also Published As

Publication number Publication date
EP4250932A4 (en) 2025-07-30
WO2022115646A1 (en) 2022-06-02
AU2021388169A9 (en) 2024-09-26
EP4250932A1 (en) 2023-10-04
MX2023006146A (es) 2023-07-31
KR20230124601A (ko) 2023-08-25
US20240000859A1 (en) 2024-01-04
CA3199153A1 (en) 2022-06-02
CN116709924A (zh) 2023-09-05
AU2021388169A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
US20240000859A1 (en) Designed bacterial compositions for treating graft-versus-host-disease
JP7165218B2 (ja) 制御性t細胞の増殖または集積を誘導するヒト由来細菌
JP6942745B2 (ja) 組成物および方法
JP2024099549A (ja) 設計された細菌組成物及びその使用
EP4233545A2 (en) Synergistic bacterial compositions and methods of production and use thereof
CA2973223A1 (en) Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome
US20220378855A1 (en) Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same
US20230125810A1 (en) Designed bacterial compositions and uses thereof
CN112118852A (zh) 用于治疗炎症性肠病的组合物和方法
US20220370553A1 (en) Prebiotic-induced anti-tumor immunity
US20240066072A1 (en) Clostrodioides difficile treatment
Nader-Macias et al. Advances in the knowledge and clinical applications of lactic acid bacteria as probiotics in the urogenital tract
WO2024193579A1 (en) Synbiotic compositions for enhancing and restoring gut epithelial barrier
RU2799556C2 (ru) Композиции и способы лечения воспалительных заболеваний кишечника
CN121057584A (zh) 设计的细菌组合物用于感染治疗的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260507